Deals

Covid Vaccine Contender CureVac More Than Triples in Debut

CureVac gets biggest first-day gain for 2020 U.S. listing
CEO says vaccine race is more against time than rivals

WATCH: CureVac Chief Executive Officer Franz-Werner Haas discusses the company’s $213 million initial public offering and updates progress on their phase one coronavirus vaccine trial.Markets: European Close." (Source: Bloomberg)

Provide news feedback or report an error

Confidential tip?

Send a tip to our reporters

Site feedback:

Take our Survey

By Crystal Tse

August 14, 2020 at 4:40 PM UTC

Updated on

August 14, 2020 at 8:39 PM UTC

This article is for subscribers only.

CureVac BV soared 249% in its trading debut after raising $213 million in a U.S. initial public offering that boosted its profile in the race for a coronavirus vaccine.

It was the best first-day performance by a wide margin among about 200 new listings on U.S. exchanges this year, according to data compiled by Bloomberg.